February 19, 2019 06:13 PM EST
R&D

Strike 3: Vi­cal ax­es its on­ly re­main­ing clin­i­cal pro­gram, com­plet­ing a tri­fec­ta of dis­as­ters

John Carroll

Editor & Founder

Vi­cal is once again turn­ing to the on­ly tool it ev­i­dent­ly knows how to use ex­pert­ly: the bud­get ax.

Fol­low­ing back-to-back clin­i­cal fail­ures lead­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times